Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics (Nasdaq: CYTK) will hold its Annual Meeting of Stockholders on May 27, 2026 at 10:00 AM PT at its headquarters, 350 Oyster Point Blvd., South San Francisco, CA.

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) will hold its Annual Meeting of Stockholders on May 27, 2026 at 10:00 AM PT at its headquarters, 350 Oyster Point Blvd., South San Francisco, CA.

Stockholders of record on March 31, 2026 may vote in person or by proxy. A live and archived webcast will be available for 12 months.

Argus May 21 session

-0.90% close to close Open Argus

Details

News Market Reaction – CYTK

On May 21, the first trading day after this news, CYTK closed 0.90% below the previous close.

Data tracked by StockTitan Argus for the May 21 session.

Market Context

This announcement sets out logistics for Cytokinetics’ Annual Meeting of Stockholders on May 27, 202...

Analysis

This announcement sets out logistics for Cytokinetics’ Annual Meeting of Stockholders on May 27, 2026, including the record date of March 31, 2026, proxy submission deadline, and webcast access with a 12‑month replay. It follows a series of recent capital raises and scientific events, while the stock trades above its 200‑day MA of 60.12 and near its 52‑week high. Investors may focus more on the CEO’s performance overview than on the procedural meeting details themselves.

Key Figures

Annual meeting date: May 27, 2026 Meeting time: 10:00 AM Pacific Time Headquarters address: 350 Oyster Point Blvd. +3 more

Annual meeting date

May 27, 2026

Scheduled date for Annual Meeting of Stockholders

Meeting time

10:00 AM Pacific Time

Scheduled start time for annual meeting

Headquarters address

350 Oyster Point Blvd.

Location of in-person annual meeting

Record date

March 31, 2026

Stockholders of record entitled to vote

Proxy deadline time

11:59 PM Eastern Time

Deadline to submit proxy on May 26, 2026

Webcast replay period

12 months

Archived replay availability on company website

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Scientific symposium

   24h Move

   +1.8%

   Announcement of CLIMB 2026 muscle biology symposium and registration details.

2. May 12

   Conference participation

   24h Move

   +3.2%

   Participation in 2026 RBC healthcare conference with a scheduled fireside chat.

3. May 11

   Clinical data update

   24h Move

   -3.1%

   New MYQORZO Phase 3 and real‑world data describing efficacy and safety signals.

4. May 08

   Equity offering close

   24h Move

   +3.5%

   Closing of public stock offering with full exercise of underwriters’ option.

5. May 06

   Equity offering pricing

   24h Move

   -0.7%

   Pricing of upsized common stock offering under existing shelf registration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

proxy card, proxy statement

2 terms

proxy card financial

"Stockholders wishing to vote must attend the meeting in person or submit a valid proxy card by mail..."

A proxy card is a document that allows shareholders to give someone else the authority to vote on their behalf at a company’s meeting. Think of it as a permission slip that ensures a shareholder’s interests are represented even if they cannot attend in person. For investors, proxy cards are important because they influence company decisions and governance, giving them a way to participate indirectly.

proxy statement regulatory

"...in accordance with instructions contained in our Proxy Statement for the 2026 Annual Meeting of Stockholders."

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance.

Stockholders of record at the close of business on March 31, 2026, are entitled to vote at Cytokinetics’ Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote must attend the meeting in person or submit a valid proxy card by mail, telephone or internet by 11:59 PM Eastern Time on May 26, 2026, in accordance with instructions contained in our Proxy Statement for the 2026 Annual Meeting of Stockholders.

Interested parties may access the live webcast of the Annual Meeting of Stockholders and the subsequent presentation at the following link: Cytokinetics Annual Meeting of Stockholders. An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer 

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
+1 (415) 290-7757

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the 2026 Cytokinetics (CYTK) Annual Meeting of Stockholders?

The 2026 Cytokinetics Annual Meeting of Stockholders is scheduled for May 27, 2026 at 10:00 AM Pacific Time. According to Cytokinetics, the meeting will take place at its headquarters in South San Francisco, California.

Who is eligible to vote at the Cytokinetics (CYTK) 2026 Annual Meeting of Stockholders?

Stockholders of record at the close of business on March 31, 2026 are entitled to vote at the meeting. According to Cytokinetics, these stockholders may vote in person or by submitting a valid proxy.

How can Cytokinetics (CYTK) stockholders vote for the 2026 Annual Meeting?

Stockholders can vote by attending in person or submitting a valid proxy by mail, telephone, or internet. According to Cytokinetics, proxy votes must be received by 11:59 PM ET on May 26, 2026 per Proxy Statement instructions.

Will the Cytokinetics (CYTK) 2026 Annual Meeting of Stockholders be available by webcast?

Yes, a live webcast of the Annual Meeting and subsequent presentation will be available via a dedicated link. According to Cytokinetics, an archived replay will remain accessible on the company’s website for twelve months.

What presentation will follow the Cytokinetics (CYTK) 2026 Annual Meeting of Stockholders?

Immediately after the meeting, President and CEO Robert I. Blum is scheduled to present an overview of Cytokinetics’ performance. According to Cytokinetics, this presentation will also be included in the live and archived webcast.

Can Cytokinetics (CYTK) stockholders ask questions during the 2026 Annual Meeting?

Yes, stockholders of record who attend in person may submit questions to management during the meeting. According to Cytokinetics, in-person attendance is required for direct participation and on-site voting at the event.